KATRINA BLACKARD: Open Payments
NPI 1467051029 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,476 in 162 payments from 24 companies in 2025. Trend: 2023 $3,208 · 2024 $3,141 · 2025 $3,476
Food & beverage: $3,459Education: $17
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $630 |
| GlaxoSmithKline, LLC. | 27 | $389 |
| HARMONY BIOSCIENCES LLC | 10 | $313 |
| Regeneron Healthcare Solutions, Inc. | 10 | $291 |
| Insmed, Inc. | 13 | $191 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $190 |
| GENZYME CORPORATION | 8 | $190 |
| Actelion Pharmaceuticals US, Inc. | 12 | $186 |
| Viatris Specialty LLC | 7 | $176 |
| Pulmonx Corporation | 1 | $150 |
Products named: DUPIXENT, FASENRA, WAKIX, NUCALA, TEZSPIRE, YUPELRI, Arikayce, CHARTIS CATHETER.
Industry payments across MS — which companies pay providers there.
